絞り込み

16644

広告

【動画】点滴をします。 (日経BP)

診察室やカンファレンスなどでよく使う医療英語のエッセンスを、今日も楽しく学んでいきましょう。 今日のトレーニングも「最初の3単語」です。診察室でよく使うこのフレ...

  1. 渦巻く銀河の形成プロセス、空飛ぶ天文台が...
  2. COP、排出削減強化で隔たり (デイリー...
  3. [医学] 胚の原腸陥入期の三胚葉のエピゲ...
  4. [医学] 癌532例を蛋白質の特徴から1...

ニュース一覧

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

著者 Heuser M , Gabdoulline R , Löffeld P , Dobbernack V , Kreimeyer H , Pankratz M , Flintrop M , Liebich A , Klesse S , Panagiota V , Stadler M , Wichmann M , Shahswar R , Platzbecker U , Thiede C , Schroeder T , Kobbe G , Geffers R , Schlegelberger B , Göhr
Ann Hematol.2017 Jun 13 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (13view , 0users)

Full Text Sources

Medical

Miscellaneous

We integrated molecular data with available prognostic factors in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) from MDS to evaluate their impact on prognosis. Three hundred four patients were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). In multivariate analysis, mutated NRAS, U2AF1, IDH2, and TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status, IPSS-R cytogenetic risk, HCT-CI > 2 and female donor sex. Mutated NRAS, IDH1, EZH2, and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The inclusion of molecular information results in better risk prediction models for OS and CIR when assessed by the Akaike information criterion. Internal cross validation confirmed the robustness of our comprehensive risk model. In summary, we propose to combine molecular, cytogenetic, and patient- and transplantation-associated risk factors into a comprehensive risk model to provide personalized predictions of outcome after alloHCT.
PMID: 28612220 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード